Oxycodone controlled-release - Intellipharmaceutics

Drug Profile

Oxycodone controlled-release - Intellipharmaceutics

Alternative Names: Abuse deterrent oxycodone hydrochloride extended release tablets - Intellipharmaceutics; Abuse-resistant oxycodone - Intellipharmaceutics; Oxycodone CR - Intellipharmaceutics; Oxycodone hydrochloride extended-release tablets - Intellipharmaceutics; Rexista oxycodone

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intellipharmaceutics International
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pain

Most Recent Events

  • 10 Oct 2017 Intellipharmaceutics intends to resubmit NDA to the US FDA for oxycodone hydrochloride extended-release tablet in the treatment of Pain
  • 25 Sep 2017 Intellipharmaceutics receives complete response letter from the FDA for oxycodone hydrochloride extended-release tablet in Pain
  • 05 Sep 2017 Intellipharmaceutics is granted two additional patents by the USPTO for its PODRAS™ Technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top